Monte Rosa Therapeutics will present preclinical NEK7 degradation research in obesity-linked inflammatory disease at ObesityWeek 2026. The Nov. 14 oral session

BWB News TV • 2026-11-13 12:51 UTC • By Billy Odell Tucker-Robinson

Monte Rosa Therapeutics will present preclinical NEK7 degradation research in obesity-linked inflammatory disease at ObesityWeek 2026. The Nov. 14 oral session extends its inflammation push after prior MRT-8102 data and a Phase 2 trial for MRT-6160.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly